Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced cancers: first human trial of ODM-212 begins

NCT ID NCT06725758

Recruiting now Disease control Sponsor: Orion Corporation, Orion Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how the drug affects the tumours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma cholangiocarcinoma colorectal cancer epithelioid hemangioendothelioma head and neck squamous cell carcinoma meningioma mesothelioma neoplasm non-small cell lung carcinoma pediatric hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOURS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Oscar Lambret

    RECRUITING

    Lille, France

    Contact Email: •••••@•••••

    Contact

  • Helsinki university Hospital

    RECRUITING

    Helsinki, Finland

    Contact

    Contact

  • Hospital 12 de Octubre

    RECRUITING

    Madrid, Spain

    Contact

    Contact Email: •••••@•••••

  • Hospital Virgen De La Macarena

    RECRUITING

    Seville, Spain

    Contact

    Contact Email: •••••@•••••

  • Institut Bergonie

    RECRUITING

    Bordeaux, France

    Contact Email: •••••@•••••

    Contact

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, France

    Contact Email: •••••@•••••

    Contact

  • Istituto Oncologico, Ospedale Bellinzona e Valli

    RECRUITING

    Bellinzona, Canton Ticino, 6500, Switzerland

    Contact Email: •••••@•••••

    Contact

  • Jefferson University Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Email: •••••@•••••

    Contact

  • Leicester Royal Infirmary

    RECRUITING

    Leicester, United Kingdom

    Contact Email: •••••@•••••

    Contact

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Email: •••••@•••••

    Contact

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Email: •••••@•••••

    Contact

  • Oulu University Hospital

    RECRUITING

    Oulu, Finland

    Contact

    Contact

  • Royal Marsden Hospital, London, UK

    RECRUITING

    London, SW36JJ, United Kingdom

    Contact Email: •••••@•••••

    Contact

  • Siteman Cancer Center

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Email: •••••@•••••

    Contact

  • Turku University Hospital

    RECRUITING

    Turku, Finland

    Contact

    Contact

  • UC Irvine Health

    RECRUITING

    Orange, California, 92868, United States

    Contact Email: •••••@•••••

    Contact

  • University of Texas, MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

    Contact

  • Valkyrie Clinical Trials

    RECRUITING

    Los Angeles, California, 90067, United States

    Contact Email: •••••@•••••

    Contact

  • Westchester Medical Center

    RECRUITING

    Valhalla, New York, 10595, United States

    Contact Email: •••••@•••••

    Contact

  • Weston Park Hospital

    RECRUITING

    Sheffield, United Kingdom

    Contact Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.